Recovery and aging of serotonergic fibers after single and intermittent MDMA treatment in dark agouti rat

Journal of Comparative Neurology

Volumn 519, Issue 12, 2011, Pages 2353-2378

  Ádori, Csaba ^a   Andó, Rómeó D ^a,b   Szekeres, Mária ^a   Gutknecht, Lise ^c   Kovács, Gábor G ^d   Hunyady, László ^a,b   Lesch, Klaus Peter ^c   Bagdy, György ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

3,4 methylenedioxymethamphetamine (MDMA; ecstasy); Aging, tryptophan hydroxylase 2 (Tph2); Brain derived neurotrophic factor (BDNF); Serotonin (5 HT)

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROTROPHIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; ASTROCYTE; BODY TEMPERATURE; BODY WEIGHT; CAUDATE NUCLEUS; CELL AGING; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROGLIA; MORPHOLOGY; MORPHOMETRICS; NONHUMAN; PARIETAL CORTEX; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; SENESCENCE; SEROTONINERGIC NERVE CELL; TEMPORAL CORTEX;

ADOLESCENT; ADULT; AGING; ANIMALS; BODY TEMPERATURE; BODY WEIGHT; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE FIBERS; RATS; RATS, INBRED STRAINS; SEROTONIN; SEROTONIN AGENTS; YOUNG ADULT;

EID: 79959735168     PISSN: 00219967     EISSN: 10969861     Source Type: Journal    
DOI: 10.1002/cne.22631     Document Type: Article

References (70)

1. Abraham H, Lazar G. 2000. Early microglial reaction following mild forebrain ischemia induced by common carotid artery occlusion in rats. Brain Res 862: 63-73.
2. Adori C, Ando RD, Kovacs GG, Bagdy G. 2006. Damage of serotonergic axons and immunolocalization of Hsp27, Hsp72, and Hsp90 molecular chaperones after a single dose of MDMA administration in Dark Agouti rat: temporal, spatial, and cellular patterns. J Comp Neurol 497: 251-269.
3. Adori C, Ando RD, Ferrington L, Szekeres M, Vas S, Kelly PT, Hunyady L, Bagdy G. 2010a. Elevated BDNF protein level in cortex but not in hippocampus of MDMA-treated Dark Agouti rats: a potential link to the long-term recovery of serotonergic axons. Neurosci Lett 478: 56-60.
4. Adori C, Zelena D, Timar J, Gyarmati Z, Domokos A, Sobor M, Furst Z, Makara G, Bagdy G. 2010b. Intermittent prenatal MDMA exposure alters physiological but not mood related parameters in adult rat offspring. Behav Brain Res 206: 299-309.
5. Alves E, Summavielle T, Alves CJ, Gomes-da-Silva J, Barata JC, Fernandes E, Bastos Mde L, Tavares MA, Carvalho F. 2007. Monoamine oxidase-B mediates ecstasy-induced neurotoxic effects to adolescent rat brain mitochondria. J Neurosci 27: 10203-10210.
6. Ando RD, Adori C, Kirilly E, Molnar E, Kovacs GG, Ferrington L, Kelly PA, Bagdy G. 2010. Acute SSRI-induced anxiogenic and brain metabolic effects are attenuated 6 months after initial MDMA-induced depletion. Behav Brain Res 207: 280-289.
7. Angelucci F, Gruber SH, El Khoury A, Tonali PA, Mathe AA. 2007. Chronic amphetamine treatment reduces NGF and BDNF in the rat brain. Eur Neuropsychopharmacol 17: 756-762.
8. Balogh B, Molnar E, Jakus R, Quate L, Olverman HJ, Kelly PA, Kantor S, Bagdy G. 2004. Effects of a single dose of 3, 4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA. Psychopharmacology (Berl) 173: 296-309.
9. Banerjee PS, Aston J, Khundakar AA, Zetterstrom TS. 2009. Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediate-early gene Arc in the juvenile and adult brain. Eur J Neurosci 29: 465-476.
10. Bonkale WL, Austin MC. 2008. 3, 4-Methylenedioxymethamphetamine induces differential regulation of tryptophan hydroxylase 2 protein and mRNA levels in the rat dorsal raphe nucleus. Neuroscience 155: 270-276.
11. Callahan BT, Cord BJ, Ricaurte GA. 2001. Long-term impairment of anterograde axonal transport along fiber projections originating in the rostral raphe nuclei after treatment with fenfluramine or methylenedioxymethamphetamine. Synapse 40: 113-121.
12. Capela JP, Carmo H, Remiao F, Bastos ML, Meisel A, Carvalho F. 2009. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 39: 210-271.
13. Carvalho F. 2009. How bad is accelerated senescence in consumers of drugs of abuse? Adicciones 21: 99-104.
14. Cho KO, Rhee GS, Kwack SJ, Chung SY, Kim SY. 2008. Developmental exposure to 3, 4-methylenedioxymethamphetamine results in downregulation of neurogenesis in the adult mouse hippocampus. Neuroscience 154: 1034-1041.
15. Colado MI, Murray TK, Green AR. 1993. 5-HT loss in rat brain following 3, 4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol 108: 583-589.
16. Cotton RG, McAdam W, Jennings I, Morgan FJ. 1988. A monoclonal antibody to aromatic amino acid hydroxylases. Identification of the epitope. Biochem J 255: 193-196.
17. Davidoff MS, Lolova IS. 1991. Age-related changes in serotonin-immunoreactivity in the telencephalon and diencephalon of rats. J Hirnforsch 32: 745-753.
18. de la Torre R, Farre M. 2004. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25: 505-508.
19. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G. 1995. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J Neurosci 15: 5476-5485.
20. Frechilla D, Insausti R, Ruiz-Golvano P, Garcia-Osta A, Rubio MP, Almendral JM, Del Rio J. 2000. Implanted BDNF-producing fibroblasts prevent neurotoxin-induced serotonergic denervation in the rat striatum. Brain Res Mol Brain Res 76: 306-314.
21. Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, O'Callaghan JP, Morgan D. 2002. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173: 183-195.
22. Graham D, Lantos P. 2002. Greenfield's neuropathology. London: Arnold.
23. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI. 2003. The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55: 463-508.
24. Grider MH, Mamounas LA, Le W, Shine HD. 2005. In situ expression of brain-derived neurotrophic factor or neurotrophin-3 promotes sprouting of cortical serotonergic axons following a neurotoxic lesion. J Neurosci Res 82: 404-412.
25. Gutknecht L, Waider J, Kraft S, Kriegebaum C, Holtmann B, Reif A, Schmitt A, Lesch KP. 2008. Deficiency of brain 5-HT synthesis but serotonergic neuron formation in Tph2 knockout mice. J Neural Transm 115: 1127-1132.
26. Gutknecht L, Kriegebaum C, Waider J, Schmitt A, Lesch KP. 2009. Spatio-temporal expression of tryptophan hydroxylase isoforms in murine and human brain: convergent data from Tph2 knockout mice. Eur Neuropsychopharmacol 19: 266-282.
27. Haan EA, Jennings IG, Cuello AC, Nakata H, Fujisawa H, Chow CW, Kushinsky R, Brittingham J, Cotton RG. 1987. Identification of serotonergic neurons in human brain by a monoclonal antibody binding to all three aromatic amino acid hydroxylases. Brain Res 426: 19-27.
28. Hatzidimitriou G, McCann UD, Ricaurte GA. 1999. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3, 4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19: 5096-5107.
29. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. 2004. Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology (Berl) 173: 383-390.
30. Jones GR. 2001. Causes of Alzheimer's disease: paracetamol (acetaminophen) today? Amphetamines tomorrow? Med Hypotheses 56: 121-123.
31. Kawano H, Takeuchi Y, Yoshimoto K, Matsumoto K, Sugimoto T. 2001. Histological changes in monoaminergic neurons of Long-Evans Cinnamon rats. Brain Res 915: 25-31.
32. Kelly PA, Ritchie IM, Quate L, McBean DE, Olverman HJ. 2002. Functional consequences of perinatal exposure to 3, 4-methylenedioxymethamphetamine in rat brain. Br J Pharmacol 137: 963-970.
33. Kindlundh-Hogberg AM, Zhang X, Svenningsson P. 2009. S100B overexpressing mutant mice exhibit prolonged behavioural and biochemical responses towards repeated intermittent binge treatments with MDMA. Int J Neuropsychopharmacol 12: 201-215.
34. Kirilly E, Molnar E, Balogh B, Kantor S, Hansson SR, Palkovits M, Bagdy G. 2008. Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: a longitudinal study over 180 days. Int J Neuropsychopharmacol 11: 795-809.
35. Kloppel S, Kovacs GG, Voigtlander T, Wanschitz J, Flicker H, Hainfellner JA, Guentchev M, Budka H. 2001. Serotonergic nuclei of the raphe are not affected in human ageing. Neuroreport 12: 669-671.
36. Kovacs GG, Ando RD, Adori C, Kirilly E, Benedek A, Palkovits M, Bagdy G. 2007. Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord. Neuropathol Appl Neurobiol 33: 193-203.
37. Lew R, Sabol KE, Chou C, Vosmer GL, Richards J, Seiden LS. 1996. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. J Pharmacol Exp Ther 276: 855-865.
38. Mamounas LA, Molliver ME. 1991. Aberrant reinnervation of rat cerebral cortex by serotonergic axons after denervation by p-chloroamphetamine (PCA). Soc Neurosci Abs. p 1181.
39. Mamounas LA, Axt KJ, Molliver ME. 1992. Abnormal morphology of regenerated 5-HT axons in rat cerebral cortex one year after ablation by p-chloroamphetamine (PCA): accelerated aging of serotonergic projections. Soc Neurosci Abs. p 629.
40. Mamounas LA, Blue ME, Siuciak JA, Altar CA. 1995. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 15: 7929-7939.
41. Mamounas LA, Altar CA, Blue ME, Kaplan DR, Tessarollo L, Lyons WE. 2000. BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain. J Neurosci 20: 771-782.
42. Martinez-Turrillas R, Moyano S, Del Rio J, Frechilla D. 2006. Differential effects of 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy") on BDNF mRNA expression in rat frontal cortex and hippocampus. Neurosci Lett 402: 126-130.
43. Mattson MP, Maudsley S, Martin B. 2004. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 27: 589-594.
44. Meyer JS, Piper BJ, Vancollie VE. 2008. Development and characterization of a novel animal model of intermittent MDMA ("Ecstasy") exposure during adolescence. Ann N Y Acad Sci 1139: 151-163.
45. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson MA. 1990. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann N Y Acad Sci 600: 649-661; discussion 661-644.
46. Mordenti J, Chappell W. 1989. The use of interspecies scaling in toxicokinetics. In: Yacogi A, Kelly J, Batra V, editors. Toxicokinetics and new drug development. New York: Pergamon Press. p 42-96.
47. Muto Y, Hayashi T, Higashi Y, Endo T, Yamamoto T, Sato K. 1999. Age-related decrease in brain-derived neurotrophic factor gene expression in the brain of the zitter rat with genetic spongiform encephalopathy. Neurosci Lett 271: 69-72.
48. Nishimura A, Ueda S, Takeuchi Y, Matsushita H, Sawada T, Kawata M. 1998. Vulnerability to aging in the rat serotonergic system. Acta Neuropathol 96: 581-595.
49. O'Shea E, Granados R, Esteban B, Colado MI, Green AR. 1998. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37: 919-926.
50. Parrott AC. 2005. Chronic tolerance to recreational MDMA (3, 4-methylenedioxymethamphetamine) or ecstasy. J Psychopharmacol 19: 71-83.
51. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. San Diego, CA: Academic Press.
52. Pedersen NP, Blessing WW. 2001. Cutaneous vasoconstriction contributes to hyperthermia induced by 3, 4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci 21: 8648-8654.
53. Piper BJ, Vu HL, Safain MG, Oliver AJ, Meyer JS. 2006. Repeated adolescent 3, 4-methylenedioxymethamphetamine (MDMA) exposure in rats attenuates the effects of a subsequent challenge with MDMA or a 5-hydroxytryptamine(1A) receptor agonist. J Pharmacol Exp Ther 317: 838-849.
54. Quate L, McBean DE, Ritchie IM, Olverman HJ, Kelly PA. 2004. Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the Dark Agouti rat. Psychopharmacology (Berl) 173: 287-295.
55. Riddle EL, Kokoshka JM, Wilkins DG, Hanson GR, Fleckenstein AE. 2002. Tolerance to the neurotoxic effects of methamphetamine in young rats. Eur J Pharmacol 435: 181-185.
56. Sabol KE, Lew R, Richards JB, Vosmer GL, Seiden LS. 1996. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations. J Pharmacol Exp Ther 276: 846-854.
57. Saper CB. 2005. An open letter to our readers on the use of antibodies. J Comp Neurol 493: 477-478.
58. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA. 1993. Serotonergic recovery after (+/-)3, 4-(methylenedioxy) methamphetamine injury: observations in rats. J Pharmacol Exp Ther 264: 1484-1491.
59. Skelton MR, Able JA, Grace CE, Herring NR, Schaefer TL, Gudelsky GA, Vorhees CV, Williams MT. 2008. (+/-)-3, 4-Methylenedioxymethamphetamine treatment in adult rats impairs path integration learning: a comparison of single vs once per week treatment for 5 weeks. Neuropharmacology 55: 1121-1130.
60. Stone DM, Merchant KM, Hanson GR, Gibb JW. 1987. Immediate and long-term effects of 3, 4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26: 1677-1683.
61. Ueda S, Sano Y, Kawata M. 1991. Collateral sprouting of serotonergic fibers in the cingulate cortex and the septum following cortical-hippocampal lesions. Brain Res 556: 329-332.
62. van Luijtelaar MG, Steinbusch HW, Tonnaer JA. 1988. Aberrant morphology of serotonergic fibers in the forebrain of the aged rat. Neurosci Lett 95: 93-96.
63. van Luijtelaar MG, Tonnaer JA, Steinbusch HW. 1992. Aging of the serotonergic system in the rat forebrain: an immunocytochemical and neurochemical study. Neurobiol Aging 13: 201-215.
64. Vorhees CV, Morford LL, Inman SL, Reed TM, Schilling MA, Cappon GD, Moran MS, Nebert DW. 1999. Genetic differences in spatial learning between Dark Agouti and Sprague-Dawley strains: possible correlation with the CYP2D2 polymorphism in rats treated neonatally with methamphetamine. Pharmacogenetics 9: 171-181.
65. Watabe Y, Yoshimoto K, Eguchi M, Ueda S. 2005. Degeneration of monoaminergic fibers in the aged micrencephalic rat. Neurosci Lett 385: 82-86.
66. Weissmann D, Belin MF, Aguera M, Meunier C, Maitre M, Cash CD, Ehret M, Mandel P, Pujol JF. 1987. Immunohistochemistry of tryptophan hydroxylase in the rat brain. Neuroscience 23: 291-304.
67. Winstock AR, Wolff K, Ramsey J. 2001. Ecstasy pill testing: harm minimization gone too far? Addiction 96: 1139-1148.
68. Xie T, Tong L, McLane MW, Hatzidimitriou G, Yuan J, McCann U, Ricaurte G. 2006. Loss of serotonin transporter protein after MDMA and other ring-substituted amphetamines. Neuropsychopharmacology 31: 2639-2651.
69. Zetterstrom TS, Pei Q, Madhav TR, Coppell AL, Lewis L, Grahame-Smith DG. 1999. Manipulations of brain 5-HT levels affect gene expression for BDNF in rat brain. Neuropharmacology 38: 1063-1073.
70. Zielasek J, Hartung HP. 1996. Molecular mechanisms of microglial activation. Adv Neuroimmunol 6: 191-122.